2 Footsie growth and income shares for your ISA

These two FTSE 100 stocks will boost your ISA’s income.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE:GSK) is one of my favourite FTSE 100 income stocks. The company is one of the most defensive businesses in the UK’s leading stock index, and as a result, its dividend stream is safer than most. 

Indeed, as a company active in the provision of consumer healthcare products, as well as vaccines and specialist medications, demand for Glaxo’s products is likely to remain robust for the foreseeable future. With such a diversified portfolio of treatments, even a huge scandal does little to dent the company’s sales and reputation.

That being said, Glaxo has struggled during the past few years, as the company lost the exclusive manufacturing rights to some its key treatments. However, management reacted quickly to right to the ship and, unlike peer AstraZeneca, Glaxo’s sales have now returned to growth as new treatments fill the void.

The company has also been helped by sterling’s devaluation. As the value of sterling against the US dollar has declined, Glaxo’s earnings have pushed higher as the majority of the company’s sales are conducted in dollars. Thanks to this devaluation boost, Glaxo’s earnings per share grew 35% last year.

Further earnings growth is expected for the next two years, as the company profits from the launch of new treatments and continues to notch up steady growth in its existing portfolio. Earnings per share growth of 8% is pencilled in for 2017 followed by growth of 3% the year after. These growth projections suggest shares in Glaxo are trading at a forward P/E of 15, falling to 14.6 for 2018.

Glaxo’s yield is probably its most attractive quality. The shares currently support a yield of 4.8%, and after recent earnings growth the payout is covered 1.4 times by earnings per share, leaving plenty of room for flexibility.

Income and growth

Cruise operator Carnival (LSE: CCL) is another dividend champion that I believe would make a great ISA investment. 

Unlike Glaxo, which is a defensive income play, Carnival is more of a long term income and growth play. At the time of writing, the shares only support a dividend yield of 2.6%, but that’s no reason to write off the company. Over the next two years analysts expect the payout to increase by 25% and as Carnival’s earnings growth gathers momentum, the payout could rise even faster.

Carnival is set to profit from both the world’s ageing population and the growing wealth of Asia’s middle class. City analysts expect the group to report revenue of $17.1bn for 2018, up nearly 10% from revenue of $15.7bn reported for 2015. Over the same period earnings per share are expected to rise 84% from $2.2 to $4.2 (336p). Based on these estimates shares in the company are trading at  forward P/E of 13.7 for 2018, which seems cheap for such a high growth business.

And it’s likely that Carnival’s growth will continue to pick up steam to the end of the decade. The company is run by an experienced management team and is benefiting from low oil prices, which are improving margins. As the number of people who can afford, and want, to go on a cruise increases, as the largest cruise operator in the world, Carnival is well placed to capitalise on the sector’s growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

10% dividend growth! 2 FTSE 100 stocks tipped to supercharge cash payouts

These FTSE 100 stocks have strong records of dividend growth. And they're expected to keep on delivering, as Royston Wild…

Read more »

Investing Articles

Down 17% in a month and yielding 7.39%! Is this FTSE 100 share a screaming buy for me?

When Harvey Jones bought Taylor Wimpey last year he thought this FTSE 100 share was a brilliant long-term buy-and-hold. Has…

Read more »

Investing Articles

Here’s how I’m using a £20k ISA to target £11k+ in income 30 years from now

Is it realistic to put £20k in an ISA now and earn over half that amount every year in passive…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

If I could only keep 5 UK stocks from my portfolio I’d save these

Harvey Jones is running through his portfolio of top UK stocks to see which ones he couldn't bear to do…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

I’m aiming for a million buying unexciting shares!

By investing regularly in long-established, proven and even rather dull businesses, this writer plans to aim for a million. Here's…

Read more »

Investing Articles

3 things to consider before you start investing

Our writer draws on his stock market experience to consider a few vital lessons he would use to start investing…

Read more »

Investing Articles

Will this lesser-known £28bn growth stock be joining the FTSE 100 soon?

As the powers that be plan a reorganisation of Footsie listing rules, this massive under-the-radar growth stock could find its…

Read more »

Investing Articles

Fools wouldn’t touch these 5 FTSE 350 flops with a bargepole – how come I own 3 of them?

Harvey Jones took a chance on three struggling FTSE 350 stocks in the hope that they'd stage a dramatic recovery.…

Read more »